摘要
目的:探讨丙戊酸联合伊马替尼对慢性粒细胞白血病细胞株K562凋亡的影响,同时探索其可能的作用机制。方法:K562细胞分别用丙戊酸、伊马替尼以及两药联合处理。检测各组细胞在药物处理后的细胞周期、细胞凋亡、Bcr/Abl mRNA水平、总蛋白激酶B(PKB)以及磷酸化PKB(p-PKB)水平。结果:丙戊酸组、伊马替尼组和两药联用组K562细胞凋亡率分别为(11.47±0.25)%、(28.43±1.70)%和(57.73±4.38)%(P<0.05),对于细胞周期各指标,两药联用组与单药组无明显差异。Bcr/Abl mRNA以及p-PKB在丙戊酸组、伊马替尼组和两药联用组的水平分别为(0.00±0.00)、(64.17±12.27)和(0.00±0.00)×109copies/(g total mRNA)以及0.25±0.02、0.17±0.01和0.08±0.01(均P<0.05),总PKB 3组细胞间无明显差异。结论:丙戊酸能协同伊马替尼促进K562细胞凋亡,其作用机制可能与降低Bcr/Abl mRNA和p-PKB水平有关。
AIM： To investigate the effects of valproate and imatinib on the apoptosis of chronic myeloid leuke- mic cell line K562. METHODS： K562 cells were divided into 3 groups and treated with valproate, imatinib and cotreat- ment, respectively. Cell cycle, apeptosis, the mRNA expression of Bcr/Abl, total protein kinase B （PKB） and phospho- rylated PKB （p-PKB） were analyzed. RESULTS： The apoptotic rates in valproate group, imatinib group and cotreatment group were （ 11.47 ±0.25 ） %, （28.43 ±1.70） % and （57.73± 4.38） %, respectively （P 〈 0.05 ）. No obvious differ- ence was observed in cell cycle between cotreatment group and monodrug group. Bcr/Abl mRNA and p-PKB in the above 3 groups were （0.00 ± 0.00）, （64.17 ± 12.27）, and （ 0.00 ± 0.00 ） x 109 copies/（ g total mRNA）, respectively （ P 〈 0. 05）, and 0.25 ±0.02, 0.17 ± 0.01 and 0.08 ± 0.01, respectively （ P 〈 0.05 ）. No apparent difference of PKB was found in the 3 groups. CONCLUSION： Valproate enhances imatinib-induced apoptosis and may link to the down-regula- tion of Bcr/Abl mRNA and p-PKB in chronic myeloid leukemic cell line K562.
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2014年第1期61-66,共6页
Chinese Journal of Pathophysiology
基金
广东省自然科学基金资助项目(No.06021340)
广东省科技厅社会发展项目(No.2009B030803033)
